Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

Inclusion Criteria: * Histologically proven advanced solid cancer for which curative therapy is not available (Part 1 only) * Histologically proven metastatic Her-2-negative breast cancer (Part 2 only) * Measurable disease by RECIST 1.1 criteria (Part 2 only) * Willing and able to consent for self to participate in study * Progressive or recurrent disease after prior systemic chemotherapy regimen * Age ≥ 18 years * ECOG performance status of 0 or 1 * Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade ≤ 1 or baseline (except alopecia) * Adequate organ function Exclusion Criteria: * Prior treatment with more than one systemic chemotherapy regimen for metastatic disease. * Prior treatment with TRC105 * History of hypersensitivity reaction to antimetabolite therapy * Receipt of an investigational agent within 28 days of starting study treatment * Prior surgery (including open biopsy), radiation therapy or systemic therapy within 28 days of starting study treatment * Minor surgical procedures within 14 days prior to first dose of TRC105 * History of brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease * Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months * Uncontrolled chronic hypertension defined as systolic \> 140 or diastolic \> 90 despite optimal therapy * Past medical history of acquired or inherited coagulopathy including patients with known hereditary hemorrhagic telangiectasia * Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days prior to first dose with TRC105 * Cardiac dysrhythmias of NCI CTCAE Grade ≥ 2 within the last month * Hemorrhage within 28 days of starting study treatment * Unhealed wounds within 28 days of starting study treatment * History of peptic ulcer disease or gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment * Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness * Known active viral or nonviral hepatitis * History of hypersensitivity reaction to human or mouse antibody products * Lung cancer with central chest lesions * Pregnancy or breastfeeding